Close Menu

A Biotech 'Cure'

Drugmaker GlaxoSmithKline has had a "miserable" year, says Forbes' Robert Langreth. Sales are "stagnant"; it's facing the loss of its patent on asthma drug Advair; its diabetes treatment, Avandia, is off the market in Europe and use of the drug was restricted in the US after the company was accused of minimizing data that show it caused heart problems; and in October, it paid $750 million to settle charges that it produced tainted drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.